307 related articles for article (PubMed ID: 19515180)
1. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Irwin N; McClean PL; Hunter K; Flatt PR
Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
[TBL] [Abstract][Full Text] [Related]
2. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.
Porter DW; Irwin N; Flatt PR; Hölscher C; Gault VA
Eur J Pharmacol; 2011 Jan; 650(2-3):688-93. PubMed ID: 21050845
[TBL] [Abstract][Full Text] [Related]
3. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
[TBL] [Abstract][Full Text] [Related]
4. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
5. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
Gault VA; McClean PL; Cassidy RS; Irwin N; Flatt PR
Diabetologia; 2007 Aug; 50(8):1752-62. PubMed ID: 17558485
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2007 Nov; 28(11):2192-8. PubMed ID: 17884253
[TBL] [Abstract][Full Text] [Related]
7. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
8. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2008 Jun; 29(6):1036-41. PubMed ID: 18291559
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
Irwin N; Hunter K; Frizzell N; Flatt PR
Regul Pept; 2009 Feb; 153(1-3):70-6. PubMed ID: 19073224
[TBL] [Abstract][Full Text] [Related]
10. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
12. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
13. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR
Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
[TBL] [Abstract][Full Text] [Related]
15. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
16. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
Lamont BJ; Drucker DJ
Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
[TBL] [Abstract][Full Text] [Related]
17. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
Gault VA; Porter DW; Irwin N; Flatt PR
J Endocrinol; 2011 Mar; 208(3):265-71. PubMed ID: 21212092
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
20. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
